Compare Citius Pharmaceuticals Inc (CTXR) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Williams-Sonoma, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Williams-Sonoma, Inc. trades at $246.37 (market cap $29.51B). The key difference: Williams-Sonoma, Inc. is far larger — about 1474.8× Citius Pharmaceuticals Inc's market cap, and Williams-Sonoma, Inc. pays a 1.21% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | WSM | |
|---|---|---|
Market Cap | $20.01M | $29.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $251.81 |
52-Week Low | $0.48 | $168.64 |
Enterprise Value | $16.23M | $30.35B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Williams-Sonoma (WSM) trades at $246.14, down 1.87% on the day, amid a generally bullish technical outlook. The stock shows strong profitability with a net income margin of 13.81% and has beaten earnings estimates for three consecutive quarters. Recent news highlights its digital-first transformation and competitive strength in home furnishings.
The outlook is supported by solid fundamentals and positive earnings momentum, but high valuation ratios and overbought RSI levels pose near-term risks. Analyst consensus is mixed, with a moderate buy rating but a price target below the current price, suggesting cautious optimism amid execution and consumer spending concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
